MARKET

CLYM

CLYM

Climb Bio
NASDAQ
13.00
+0.34
+2.71%
Opening 15:52 06/26 EDT
OPEN
12.51
PREV CLOSE
12.66
HIGH
13.14
LOW
12.42
VOLUME
758.39K
TURNOVER
--
52 WEEK HIGH
13.46
52 WEEK LOW
1.170
MARKET CAP
744.56M
P/E (TTM)
-16.7601
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), Climb Bio (CLYM) and Ionis Pharmaceuticals (IONS)
TipRanks · 1d ago
Climb Bio Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target
Benzinga · 2d ago
Climb Bio Buy Rating Reiterated as Advancing Pipeline Supports Maintained $20 Price Target
TipRanks · 2d ago
Weekly Report: what happened at CLYM last week (0615-0619)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG)
TipRanks · 06/15 11:31
Weekly Report: what happened at CLYM last week (0608-0612)?
Weekly Report · 06/15 09:50
Climb Bio Establishes New At-the-Market Equity Program
TipRanks · 06/12 22:46
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.